基于新靶点的抗立克次体药物研究进展
x

请在关注微信后,向客服人员索取文件

篇名: 基于新靶点的抗立克次体药物研究进展
TITLE: Research progress on anti-rickettsial drugs against novel targets
摘要: 立克次体是以节肢动物为传播媒介、专性胞内寄生的革兰氏阴性菌,其所致立克次体病是一类严重的人兽共患传染病。当前该病临床防控面临疗效有限、不良反应显著及耐药性日益突出等挑战,而新型抗立克次体药物的研发长期处于停滞状态。本文系统梳理立克次体的完整生命周期,聚焦入侵、吞噬体逃逸、代谢、免疫逃逸及胞内复制与传播等环节中可药物干预的关键靶点,如表面细胞抗原2、外膜蛋白B、核苷酸转位酶1、Ⅰ型和Ⅳ型分泌系统及立克次体表面蛋白A等。近年来,靶向这些新靶点的抗立克次体化合物研究取得了一定的进展,已发现多类候选分子与候选药物,包括阻断病原体入侵与传播的候选分子、干扰能量及物质代谢的候选分子、靶向分泌系统的候选分子,以及调节宿主免疫应答的药物。然而,多数研究局限于体外实验或虚拟筛选阶段,尚缺乏系统的体内药效学评价与安全性验证。未来应整合结构生物学、多组学技术及体内外模型以确证靶点并评估其成药性,同时探索联合用药策略,以突破新型抗立克次体药物的研发困境。
ABSTRACT: Rickettsia are Gram-negative obligate intracellular bacteria transmitted by arthropod vectors, and the rickettsioses they cause, constitute a group of serious zoonotic infectious diseases. Current clinical management of rickettsioses faces challenges including limited therapeutic efficacy, marked adverse reactions, and increasing drug resistance, whereas the development of novel anti-rickettsial drugs has long remained stagnant. This review systematically summarizes the complete life cycle of Rickettsia , focusing on key stages amenable to pharmacological intervention, including invasion, phagosomal escape, metabolism, immune evasion, and intracellular replication and cell-to-cell spread. Potential drug targets highlighted in these processes include surface cell antigen 2, outer membrane protein B, nucleotide translocase 1, type Ⅰ/type Ⅳ secretion system, and rickettsial surface protein A. Recently, research on anti-rickettsial compounds against these novel targets has made some progress, and multiple classes of candidate molecules and candidate drugs have been reported, including candidate molecules blocking pathogen invasion and spread, candidate molecules interfering with energy and substance metabolism, candidate molecules targeting secretion systems, and candidate drugs modulating host immune responses. Nevertheless, most existing studies remain confined to in vitro experiments or virtual screening, lacking systematic in vivo pharmacodynamic evaluation and safety verification. Future efforts should integrate structural biology, multi-omics technologies, and both in vitro and in vivo models to validate these targets and assess their druggability, and to explore combination therapeutic strategies, so as to break through the current predicament in the development of novel anti-rickettsial drugs.
期刊: 2026年第37卷第21期
作者: 李玉凤;刘幸;张光云;李帅阳;沈磊
AUTHORS: LI Yufeng,LIU Xing,ZHANG Guangyun,LI Shuaiyang,SHEN Lei
关键字: 立克次体;抗立克次体药物;药物靶点;生命周期;外膜蛋白B
KEYWORDS: Rickettsia ;anti-rickettsial drugs;drug targets;life cycle;outer membrane protein B
阅读数: 2 次
本月下载数: 0 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!